TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

Abstract

The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias, as well as other CD40+ malignancies. The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interacon. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies, chemotherapeutic agents, chemotherapy cocktails, and radiotherapy.